10-Q: Mosaic ImmunoEngineering Faces Going Concern Warning

Mosaic ImmunoEngineering, a development-stage biotech, reported significant cash depletion and a going concern warning, with a key acquisition agreement expiring and multiple board resignations.

Summary

• The company reported cash and cash equivalents of $31,761 as of September 30, 2025, a significant decrease from $115,019 at December 31, 2024.
• Total liabilities increased to $7,362,181 at September 30, 2025, from $6,929,785 at December 31, 2024.
• The accumulated deficit grew to $(9,357,029) as of September 30, 2025, compared to $(8,838,320) at December 31, 2024.
• Net loss for the nine months ended September 30, 2025, was $(518,709), an improvement from $(768,939) for the same period in 2024, primarily due to reduced operating expenses.
• Research and development expenses decreased to $47,848 for the nine months ended September 30, 2025, from $167,617 in the prior year period.
• General and administrative expenses decreased to $420,138 for the nine months ended September 30, 2025, from $561,881 in the prior year period.
• The binding term sheet with Oncotelic Therapeutics, Inc. for a strategic acquisition, valued at up to $30 million in stock and milestones, expired on June 30, 2025.
• The company received a notice of termination from CWRU for a license agreement effective March 22, 2024, and previously terminated a September 2021 license agreement with UC San Diego on July 12, 2023.
• Management has raised substantial doubt about the company's ability to continue as a going concern, as current cash will not satisfy operational and capital requirements for the next twelve months.

Sentiment

Score: 2

Explanation: The company faces severe financial distress, evidenced by critically low cash, increasing liabilities, an explicit going concern warning, and the failure of a key strategic acquisition. Management turnover and the termination of license agreements further highlight operational instability and a lack of clear path to sustainable funding or revenue.

Positives

• Net loss for the nine months ended September 30, 2025, decreased to $(518,709) from $(768,939) in the prior year period.
• Net cash used in operating activities for the nine months ended September 30, 2025, decreased to $(83,258) from $(220,442) in the prior year period, indicating a reduced cash burn rate.

Negatives

• Cash and cash equivalents significantly declined to $31,761 as of September 30, 2025, from $115,019 at December 31, 2024.
• Total liabilities increased to $7,362,181 at September 30, 2025, from $6,929,785 at December 31, 2024.
• The accumulated deficit continued to grow, reaching $(9,357,029) as of September 30, 2025.
• The binding term sheet for the strategic acquisition of Oncotelic's cancer therapies and AI technologies expired on June 30, 2025, failing to materialize.
• The company received a notice of termination for its License Agreement with CWRU effective March 22, 2024, and previously terminated a significant license agreement with UC San Diego in July 2023.
• Multiple key management and board members resigned in August 2025, including the EVP, Chief Financial Officer, and two directors.
• The company has not yet generated any revenues and its ability to continue operations is highly dependent on raising additional capital.

Risks

• Substantial doubt exists regarding the company's ability to continue as a going concern due to insufficient cash and lack of revenue.
• Inability to raise additional capital on commercially reasonable terms, or at all, will delay or prevent the company from conducting business operations.
• Any additional equity financing may involve substantial dilution to existing stockholders.
• Debt financing, if obtained, may involve significant cash payment obligations and restrictive covenants.
• The company's limited cash position has required it to perform only limited development activities and to delay and scale back development programs.
• There is a risk of cessation of operations altogether if sufficient funds are not raised.
• Disruptions caused by COVID-19, broad-based inflation, and potential economic recession may adversely impact the ability to fund future operations.
• The company is involved in a dispute over escrowed shares from the Crossflo acquisition, with a potential obligation of approximately $256,000 if the claim fails.

Future Outlook

The company anticipates that its current cash and cash equivalents will not satisfy operational and capital requirements for the next twelve months. Its ability to continue operations is highly dependent on raising additional capital, for which there are no current arrangements. The inability to obtain financing will delay the ability to conduct business operations, including supporting research and development efforts, hiring staff, and reducing current liabilities. The company may be required to cease operations altogether if it continues to have insufficient funds.

Management Comments

• Management believes that the resolution of the Crossflo escrow shares issue will probably not result in a material obligation to the company.
• Steven King, President, CEO, Principal Financial Officer, and Principal Accounting Officer, certified that the report fairly presents the financial condition and results of operations and that disclosure controls and procedures were effective as of September 30, 2025.

Industry Context

As a development-stage biotechnology company, Mosaic ImmunoEngineering operates in an industry characterized by high capital requirements for research, development, and clinical trials. The company's current financial state, marked by critically low cash reserves, increasing liabilities, and an explicit 'going concern' warning, places it in a highly precarious position. The termination of key license agreements and the expiration of a binding term sheet for a strategic acquisition highlight significant challenges in securing and advancing a product pipeline, which is fundamental for survival and growth in the biotech sector. The current economic climate, including inflation and recession concerns, further exacerbates the difficulty for early-stage biotechs to attract necessary investment.

Comparison to Industry Standards

• Mosaic ImmunoEngineering's financial health is significantly below industry standards for a viable biotechnology company, particularly one focused on cancer therapies, which typically require substantial, sustained capital investment.
• Unlike many comparable development-stage biotechs that secure significant funding rounds to advance clinical pipelines, Mosaic has critically low cash reserves ($31,761) and an explicit going concern warning, indicating an inability to fund operations for the next 12 months.
• The failure to complete the Oncotelic acquisition, a potential $30 million deal, and the termination of multiple license agreements (CWRU, UC San Diego) demonstrate a lack of progress in building a robust intellectual property and product pipeline, a stark contrast to successful peers who actively expand and de-risk their portfolios.
• The reduction in R&D and G&A expenses, while improving net loss and cash burn, is a symptom of financial distress rather than strategic growth, suggesting a contraction of development activities rather than expansion, which is atypical for a company aiming to commercialize cancer therapies.
• The multiple resignations of board members and the CFO, with the CEO assuming multiple financial roles, indicate instability in corporate governance and management capacity, which is generally viewed negatively compared to the stable leadership structures of well-funded industry players.

Management Changes

Legal Proceedings

• The company is involved in a dispute regarding escrowed shares from the 2008 Crossflo acquisition, seeking the return of 5,690 common shares due to incurred damages. If the company fails to prevail, it may be obligated to deposit approximately $256,000 in cash.

Related Party Transactions

• Consulting agreements (retroactive to September 1, 2020) were entered into with Nicole Steinmetz, Ph.D. (former acting Chief Scientific Officer and Board member), Jonathan Pokorski, Ph.D. (Dr. Steinmetz's spouse), and Steve Fiering, Ph.D., all co-founders and greater than 5% shareholders. These agreements involve deferred compensation and RSU grants.
• Three former members of the Board of Directors invested $225,000 in aggregate in the May 2021 convertible notes.
• One current and four former members of the Board of Directors invested $155,000 in aggregate in the February 2022 convertible notes.
• Steven King, the company's President and CEO, is a shareholder (less than 1% ownership), board member, and paid advisor of Oncotelic Therapeutics, Inc.

Stakeholder Impact

• Shareholders face significant risk of dilution from potential future equity financings and the potential loss of investment if the company ceases operations due to the going concern warning.
• Employees and consultants have experienced reduced time commitments and deferred compensation, indicating job insecurity and financial strain.
• Creditors, particularly holders of convertible notes and the loan payable, face increased risk of delayed or non-payment given the company's severe liquidity issues.
• Partnerships with CWRU and UC San Diego have been terminated or scaled back, impacting potential future collaborations and technology development.
• The failure of the Oncotelic acquisition impacts the company's ability to establish a new product pipeline, affecting future strategic direction and potential for growth.

Next Steps

• Raise additional capital through equity and/or debt offerings to fund future operations and meet capital requirements.
• Identify new product candidates and license or acquire those rights to establish a new product pipeline.
• Support research and development efforts for new potential product candidates.
• Hire additional staff, including clinical, scientific, operational, financial, and management personnel.
• Reduce current liabilities to improve financial stability.

Key Dates

Recommendation

The company faces severe financial distress with an explicit going concern warning, critically low cash reserves, increasing liabilities, and no clear path to sustainable funding or revenue. The failure of a key strategic acquisition and multiple board resignations further underscore the precarious operational and financial state, making it a high-risk investment with significant downside potential. The company's ability to continue operations is highly uncertain, and investors face a substantial risk of capital loss.

Keywords

Biotechnology, Cancer Therapies, ImmunoEngineering, SEC Filing, 10-Q, Going Concern, Biotech Funding, Corporate Governance, Financial Distress, Oncology, Clinical Development